Not exact matches
In short, bears have suggested that
oliceridine's target market is only a small fraction of the broader acute - pain space, and Trevena may be unable to convince payers to provide coverage
for what will almost certainly be a far more expensive drug than morphine.
Those are definitely fair arguments that could play a huge role if
oliceridine doesn't clearly differentiate itself from morphine in both of these trials — and underscore why investors may want to keep any position on the small side
for the time being.
George Budwell (Trevena): The clinical - stage biotech Trevena is set to release top - line results from two phase 3 studies (APOLLO - 1 and APOLLO - 2)
for its lead drug candidate,
oliceridine, in the first quarter of 2017.
Trevena, a firm based in Chesterbrook, Pennsylvania, announced on 2 November that it has submitted
oliceridine, an intravenous opioid meant
for use in hospitalized patients, to FDA
for marketing approval.